Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Sell
46
DGX Quote, Financials, Valuation and Earnings
Last price:
$167.08
Seasonality move
:
-4.11%
Day range:
$165.45 - $167.76
52-week range:
$137.71 - $182.38
Dividend yield:
1.86%
P/E ratio:
21.12x
P/S ratio:
1.87x
P/B ratio:
2.69x
Volume:
1.1M
Avg. volume:
873.8K
1-year change:
12.4%
Market cap:
$18.6B
Revenue:
$9.9B
EPS (TTM):
$7.91
Analysts' Opinion
-
Consensus RatingQuest Diagnostics has received a consensus rating of Hold. The company's average rating is a Hold based on 8 Buy ratings, 9 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $184.10, Quest Diagnostics has an estimated upside of 10.22% from its current price of $167.03.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $158.69 representing 4.99% downside risk from its current price of $167.03.
Fair Value
-
According to the consensus of 17 analysts, Quest Diagnostics has 10.22% upside to fair value with a price target of $184.10 per share.
DGX vs. S&P 500
-
Over the past 5 trading days, Quest Diagnostics has underperformed the S&P 500 by -3.86% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Quest Diagnostics does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Quest Diagnostics has grown year-over-year revenues for 5 quarters straight. In the most recent quarter Quest Diagnostics reported revenues of $2.7B.
Earnings Growth
-
Quest Diagnostics has grown year-over-year earnings for 3 quarters straight. In the most recent quarter Quest Diagnostics reported earnings per share of $1.94.
Enterprise value:
24.4B
EV / Invested capital:
--
Price / LTM sales:
1.87x
EV / EBIT:
17.04x
EV / Revenue:
2.41x
PEG ratio (5yr expected):
3.27x
EV / Free cash flow:
23.14x
Price / Operating cash flow:
17.95x
Enterprise value / EBITDA:
12.52x
Gross Profit (TTM):
$3.3B
Return On Assets:
5.91%
Net Income Margin (TTM):
8.83%
Return On Equity:
13.14%
Return On Invested Capital:
7.26%
Operating Margin:
13.05%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $9.6B | $9.3B | $10.2B | $2.4B | $2.7B | |
| Gross Profit | $3.2B | $3.1B | $3.3B | $771M | $863M | |
| Operating Income | $1.2B | $1.3B | $1.4B | $300M | $346M | |
| EBITDA | $1.6B | $1.7B | $2B | $431M | $488M | |
| Diluted EPS | $6.78 | $7.43 | $7.91 | $1.72 | $1.94 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $3B | $2.5B | $1.8B | $2.2B | $2.1B | |
| Total Assets | $13.9B | $13.4B | $12.8B | $14B | $15.8B | |
| Current Liabilities | $1.7B | $1.7B | $1.4B | $2.3B | $1.4B | |
| Total Liabilities | $7.1B | $6.9B | $6.6B | $7.4B | $8.8B | |
| Total Equity | $6.9B | $6.5B | $6.2B | $6.5B | $7B | |
| Total Debt | $4B | $4B | $4B | $4.7B | $5.9B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $1.3B | $1.3B | $1.5B | $154M | $314M | |
| Cash From Investing | -$532M | -$1.1B | -$2.5B | -$213M | -$115M | |
| Cash From Financing | -$1.3B | $83M | $676M | -$153M | -$561M | |
| Free Cash Flow | $864M | $947M | $1.1B | $50M | $197M | |
DGX
Sector
Market Cap
$18.6B
$34.4M
Price % of 52-Week High
91.59%
48.88%
Dividend Yield
1.86%
0%
Shareholder Yield
--
-1.01%
1-Year Price Total Return
12.4%
-37.36%
Beta (5-Year)
0.492
0.614
Dividend yield:
1.86%
Annualized payout:
$2.96
Payout ratio:
37.46%
Growth streak:
13 years
Technicals
8-day SMA
Sell
Level
$170.18
200-day SMA
Buy
Level
$164.51
Bollinger Bands (100)
Sell
Level
167.7 - 177.64
Chaikin Money Flow
Sell
Level
-969.7K
20-day SMA
Sell
Level
$175.26
Relative Strength Index (RSI14)
Sell
Level
31.73
ADX Line
Sell
Level
33.1
Williams %R
Buy
Level
-85.5758
50-day SMA
Sell
Level
$175.30
MACD (12, 26)
Buy
Level
45.92
25-day Aroon Oscillator
Sell
Level
-76
On Balance Volume
Sell
Level
-1.2M
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.8068)
Buy
CA Score
(Annual)
Level (-0.0945)
Buy
Beneish M-Score
(Annual)
Level (-2.5412)
Buy
Momentum Score
Level (9)
Buy
Ohlson Score
Level (-0.4562)
Buy
Piotroski F Score
(Annual)
Level (4)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (9)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Quest Diagnostics Inc is a leading independent provider of diagnostic testing, information, and services in the us. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.
Stock Forecast FAQ
In the current month, DGX has received 8 Buy ratings 9 Hold ratings, and 0 Sell ratings. The DGX average analyst price target in the past 3 months is $184.10.
-
Where Will Quest Diagnostics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Quest Diagnostics share price will rise to $184.10 per share over the next 12 months.
-
What Do Analysts Say About Quest Diagnostics?
Analysts are divided on their view about Quest Diagnostics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Quest Diagnostics is a Sell and believe this share price will drop from its current level to $158.69.
-
What Is Quest Diagnostics's Price Target?
The price target for Quest Diagnostics over the next 1-year time period is forecast to be $184.10 according to 17 Wall Street analysts, 8 of them rate the stock a Buy, 0 rate the stock a Sell, and 9 analysts rate the stock a Hold.
-
Is DGX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Quest Diagnostics is a Hold. 9 of 17 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of DGX?
You can purchase shares of Quest Diagnostics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Quest Diagnostics shares.
-
What Is The Quest Diagnostics Share Price Today?
Quest Diagnostics was last trading at $167.08 per share. This represents the most recent stock quote for Quest Diagnostics. Yesterday, Quest Diagnostics closed at $167.03 per share.
-
How To Buy Quest Diagnostics Stock Online?
In order to purchase Quest Diagnostics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
How High Can SharkNinja Stock Go?
If you know popular consumer appliance brands Shark and Ninja,…
Stock Ideas
Buy
70
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 58x
Buy
62
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
82
SBET alert for Jul 17
SharpLink Gaming [SBET] is down 8.43% over the past day.
Buy
89
EXOD alert for Jul 17
Exodus Movement [EXOD] is down 0.39% over the past day.
Buy
60
U alert for Jul 17
Unity Software [U] is up 14.41% over the past day.
